Hepatitis C virus infection in jail: Difficult-to-reach, not to-treat. Results of a point-of-care screening and treatment program
| Autor: | Mario Masarone, Maria Rosaria Attianese, Rosa Caruso, Carmine Izzo, Giuseppe De Matteis, Marcello Persico, Andrea Aglitti, Antonio Pagano |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Adult
Male Pediatrics medicine.medical_specialty Sustained Virologic Response Point-of-Care Systems Hepatitis C virus Hepacivirus Direct antiviral agents medicine.disease_cause Antiviral Agents Point-of-care screening and treatment Young Adult 03 medical and health sciences 0302 clinical medicine People in conviction Prevalence medicine Humans Prospective Studies Antiviral treatment Aged Point of care Hepatology business.industry Gastroenterology Antiviral therapy virus diseases Refusal to Treat Hepatitis C Antibodies Middle Aged Hepatitis C digestive system diseases Hcv elimination HCV infection Sustained virological response Italy Prisons 030220 oncology & carcinogenesis Conviction Female Lost to Follow-Up 030211 gastroenterology & hepatology Observational study business Clinical record |
| Zdroj: | Digestive and Liver Disease. 52:541-546 |
| ISSN: | 1590-8658 |
| DOI: | 10.1016/j.dld.2020.02.012 |
| Popis: | Background An unmet objective in the pursuit of HCV elimination is the creation of a simple and fast operating model to identify difficult-to-treat populations, like prisoners. Of many obstacles, the first is represented by the poor knowledge of inmates HCV-Ab prevalence. Moreover, due to the peculiar status of conviction, often their access to antiviral therapy is neglected. Aims To evaluate the prevalence of HCV infection in a penitentiary Institution of Southern Italy through a point-of-care screening and treatment program. Methods We conducted a prospective observational study in two phases: first, we reviewed all the prisoners’ clinical records, to verify HCV-Ab execution. Subsequently, we performed a universal point-of-care screening and treatment program. Results We enrolled 670 patients. Overall, 310(46.27%) were already HCV-Ab tested. At the screening initiation, 23.28% patients were discharged, whereas 8.35% refused. Of the remaining 458 subjects, 58(12.67%) were HCV-Ab positive and 46 HCVRNA positive. All these underwent DAA, obtaining 100% SVR. At the end of the program, a total of 491(73.28%) subjects had HCV-Ab available. Sixty-nine (14.05%) were positive. A total of 214(31.94%) subjects were lost to follow-up. Conclusions We revealed a prevalence of 14.05% of HCV-Ab in conviction. Antiviral treatment was safe and efficacious. More efforts are advisable to provide screening for HCV-Ab in conviction. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect